Background and Aim: The aim of this study is to determine the relationship between CDC25A gene polymorphism and pancreatic cancer via determining CDC25A gene expression and polymorphisms of tumor tissues of pancreatic cancer cases. Additionally, it is aimed to prove the possible relationship between cancer development and the gene expression level with determining CDC25A gene expression levels in tumor tissue and normal tissue.
INTRODUCTION
Pancreatic cancer is the most common cause of mortality associated with gastrointestinal cancer and is the fourth most common cause of cancer-related death in the United States 1 .
In the same way, 5-year survival rate is unfortunately less than 5 % due to the late presentation of patients widely affected so it also makes therapeutic intervention difficult. 2 Surgical resection is the only method for potential treatment, however, this is only applied to only 10-20 % of patients with pancreatic cancer. 3 5-year survival of the patients to whom pancreatoduodenectomy (Whipple procedure) is applied is healed and approaches to 20 %. 4 Significantly, when cancers smaller than 2 cm in diameter are confined to the pancreas and detected at an early stage, 5-year survival is higher and may approach to 46 % 4 . For this purpose, the detection of early-stage pancreatic cancer including preneoplastic lesions in patients at average and high risk (they are labeled as pancreatic intraepithelial neoplasia or PanIN) can significantly provide an opportunity to reduce pancreatic cancer mortality.
There is a period of approximately 10-20 years in the development of most cancers and this period is a sufficient period for preventive treatment. Overexpression of CDC25a has been reported in many human cancers. Even, the over-expression of this gene is associated with the extreme aggressiveness of the disease and poor prognosis 5 . CDC25 phosphatases are involved in cell differentiation, tumorigenesis, cell cycle checkpoints and apoptosis 6 . Because of the roles of CDC25 phosphatases about the fate of the cell, they should be tightly regulated during the cell division cycle. Also, CDC25 phosphatases should be inactivated in the checkpoint activation response in order to stop the progression of the cell cycle and to allow time to the cell for DNA repair or apoptosis. Wrongly editing any of these processes can result in genomic instability.
In a study made on head and neck cancer, over-expression of CDC25A and CDC25B has been worked with quantitative RT-PCR method. It was reported that CDC25 mRNA is overexpressed in 80% of cases and it was expresses 5 times more in 55% of them when compared to normal mucosa control 7 . CDC25A and CDC25B over-expression was observed in human gastric carcinoma 8 .
In another study performed, gene structures of three isoforms and also splice variants, mRNA and protein expressions of CDC25 phosphatases were studied in human colorectal cancer and their relationship with patients' development and tumor pathological characteristics were evaluated. It has been shown that these phosphatases were regulated differently in colorectal carcinomas and could be included in the tumor development. The expression levels were found to be correlated with the lifetime and clinicopathological characteristics of the patient 9 .
It has been reported that CDC25A was over-expressed in 47% of early stage breast cancer cases and this situation is associated with bad situation 10 . In another study investigating CDC25A and CDC25B expression levels immunohistochemically in breast cancer, similar results were obtained. In 69.6% of cases, high level of CDC25A has been reported 11 .
CDC25A phosphatase is thought to have a place in the diagnosis and treatment of cancer due to over-expression observed in many cancer types and its critical role in cell cycle control. Although CDC25A was studied and found high in many cancer cases, there is only one study with pancreatic cancer. In that study, it was observed that the expression of CDC25B from CDC25 gene family was high but CDC25A and CDC25C had normal expression levels in contrast to other cancer cases. Data of 48 patients were evaluated and gene expression was only investigated in this study 12 .
In this study, our aim is to determine the relationship between CDC25A gene polymorphisms with pancreatic cancer by putting out CDC25A gene expression and polymorphisms in the tumor tissues of pancreas cancer patients. For this purpose, we tried to make the literature data more comprehensive by determining CDC25A expressions in normal and cancerous tissues of 28 patients who received surgery and CDC25A polymorphisms in blood of 118 patients and 83 healthy individuals.
MATERIALS and METHODS

Study Populations
28 pancreatic cancer patients who received surgery, 90 pancreatic cancer patients without surgery and 83 healthy individuals were included into the study group. Tumor and neighboring healthy tissues from material taken in operation from 28 pancreatic cancer patients operated in Department of General Surgery according to treatment protocols were obtained and placed in a nitrogen tank. In addition, blood samples were taken from a total of 90 pancreatic cancer patients followed by Department of Medical Oncology and stored at -20 °C until DNA isolation procedure. For polymorphism study, blood samples were taken from 83 volunteers who they and their first-degree relatives didn't have a cancer history. The study was approved by the Institutional Review Board of Faculty of Medicine in XXX University (Ethic Committee Voucher no: 24.05.2010/5).
DNA and RNA Isolation
For DNA isolation from blood, peripheral blood samples (5 ml) were collected by venipuncture into sterile siliconized vacuum tubes with 2 mg/ml disodium EDTA. Immediately after collection, whole blood was stored at -20 o C until its use. Genomic DNA was extracted from whole blood using standard proteinase K digestion and after the salting-out, stored at -20 o C. For DNA isolation from both tumor and adjacent normal pancreas tissues, High Pure Template Preparation Kit (Roche, Mannheim, Germany) was used.
For RNA isolation from both tumor and adjacent normal pancreas tissues of 28 patients, High Pure RNA Tissue Kit (Roche, Mannheim, Germany) was used.
Expression Analysis RNA samples obtained from tumor and adjacent normal pancreas tissues were converted to cDNA by using Precision qScript Reverse Transcription (PrimerDesign, Southampton, UK). Veriti™ Dx 96-Well Thermal Cycler (Applied Biosystem, Foster City, CA, USA) was used in thermal cycling processes in obtaining cDNA. PCR was performed using MJ Research PTC-200 PCR Machine (GMI, Minnesota, USA) for CDC25A expression. The sets of primers designed for CDC25A were forward 5'-GCTGCAGGGTCTGGGCAGTGAT-3' and reverse 5'-TCTGTTGACTCGGAGGAGCCCA-3' and for GAPDH were forward 5'-AGACCACAGTCCATGCCATCAC-3' and reverse 5'-GGTCCACCACCCTGTTGCTGT-3' as housekeeping gene.
Restriction Fragment Length Polymorphism (Rflp)
Before RFLP experiments, PCR optimization was realized for 2 pairs of primers designed for Ser88Phe and rs3731485. Nucleotide sequences of the PCR primer sets, sizes of the amplicons, and annealing temperatures are listed in Table 1 . Patient group's mean age was 64.2 (63.4 for female, 65 for male) and control group's mean age was 56.3 (57 for female, 55.6 for male).
When we evaluated the symptoms seen in the patients included in the study, we showed that the most frequently cause referred to the clinic was jaundice and weight loss. 59.3% (70 patients) of 118 patients included in the study had one or more comorbids (A total of 110 comorbids in 70 patients). The most common comorbid is diabetes mellitus (DM) with 59%. 68% (17 patients) and 32% (8 patients) of cardiovascular disease are hypertension (HT) and coronary artery disease (CAD), respectively. All of the respiratory disease was chronic obstructive pulmonary disease.
When our 118 patients were analyzed in terms of CA 19-9 and CEA as tumor markers, CA 19-9 and CEA levels were normal in 18.6% of patients (22 patients), CA 19-9 level was high and CEA level was normal in 54.2% (64 patients) and CA 19-9 and CEA levels were high in 27.1% (32 patients).
USG, abdominal CT, ERCP and MRCP were used for the patients as imaging methods. Abdominal CT and ultrasound were used most frequently. When all of 118 patients were evaluated according to their pathology reports, all of them were classified as adenocarcinoma in terms of pathological types.
When pancreatic cancer and control groups were classified for Ser88Phe polymorphisms of CDC25A gene in terms of C/C, C/T, T/T genotype frequencies, 97.5% (115 patients) had C/C, 0.8% (1 patient) had C/T and 1.7% (2 patients) had T/T genotype of the cancer group while 97.6% (80 patients) had C/C, 2.4% (2 patients) had C/T and no patient had T/T genotype of the control group. When pancreatic cancer and control groups were classified for Ser88Phe polymorphisms of CDC25A gene in terms of C and T allele frequencies, it was shown that 97.9% (231 patients) had C allele and 2.1% (5 patient) had T allele of the cancer group while 98.8% (162 patients) had C allele and 1.2% (2 patient) had T allele of the control group. When pancreatic cancer and control groups were compared or Ser88Phe polymorphisms of CDC25A gene in terms of C/C, C/T, T/T genotype frequencies and C and T allele frequencies, no statistically significant difference was detected (p>0.05, Table 2 ). When pancreatic cancer and control groups were classified for rs3731485 polymorphisms of CDC25A gene in terms of C/C, C/G, G/G genotype frequencies, 94.9% (112 patients) had C/C, 2.5% (3 patient) had C/G and 2.5% (3 patients) had G/G genotype of the cancer group while 92.2% (71 patients) had C/C, 5.2% (4 patients) had C/G and 2.6% (2 patients) had G/G genotype of the control group. When pancreatic cancer and control groups were classified for rs3731485 polymorphisms of CDC25A gene in terms of C and G allele frequencies, it was shown that 96.2% (227 patients) had C allele and 3.8% (9 patient) had G allele of the cancer group while 94.8% (146 patients) had C allele and 5.2% (8 patient) had G allele of the control group. When pancreatic cancer and control groups were compared or rs3731485 polymorphisms of CDC25A gene in terms of C/C, C/T, T/T genotype frequencies and C and T allele frequencies, no statistically significant difference was found (p>0.05, Table 3 ) Table 3 . Genotype distributions and allele frequencies for CDC25A gene rs3731485 polymorphism in the patient and control groups. Fisher's chi-square test, OR: odds ratio CDC25A gene expression was studied in tumor and neighboring healthy tissues from material taken in operation from 28 pancreatic cancer patients operated in our study. Reference range was between 0.5 and 1.5. If the expression value was below 0.5, the expression was decreased. If the expression value was higher than 1.5, the expression was increased. If the expression value was between 0.5 and 1.5, the expression was normal. As a result of our result, the expression level was incresed in 7.14% (3 patients), decreased in 3,57% (1 patient) and normal in 89.28% (25 patients) of 28 patients ( Figure  1 ). Statistical analysis performed on expression levels obtained showed that there was no statistically significant difference between pancreatic cancer and control groups in terms of CDC25A gene expression (p>0.05).
DISCUSSION
Many studies demonstrated different genetic and epigenetic alterations, including K-ras proto-oncogene and p53, Smad4/ DPC4 and p16/CDKN2A tumor suppressor gene mutations, in PDAC 13 . Also, over-expression of growth factors and growth factor receptors is observed in most of these tumors and PDACs causes many important changes in regulatory pathways of apoptosis, invasion and metastasis [14] [15] [16] . PDAC is characterized by uncontrolled cell cycle progression, cell cycle arrest and resistance to apoptosis, and these are associated with both mutations in K-ras and p53 protooncogenes and Smad4/DPC4 and p16/CDKN2A tumor suppressor gene mutations 16 . CDC25A overexpression has been seen in many human cancers and this shows that it may take role in the development of malignant transformation and pathogenesis of these phosphatases. Therefore, we tried to evaluate the role of CDC25A gene in cell cycle progression by analyzing this gene expression and polymorphism in PDAC in this study.
Deregulation of cell cycle control mechanism is thought to play a key role in the malignant transformation of cells 17 . The changes in genes regulating the cell cycle are often encountered in human cancers 18 and the cell proliferation reflecting cell cycle progression contributes to the aggressive growth pattern of cancer cells. Two critical control points have been identified and are included in the G1-S phase and G2M phase change. The major components in the cell cycle system are cyclins and their corresponding cyclin dependent kinases (CDK). CDK/ cyclin complexes are activated and deactivated sequentially to regulate the different phases of the cell cycle. The progress of the cell cycle deregulation in PDAC is associated a number of mutations in different genes; tumor suppressor p53 gene preventing anti-apoptotic responses and standby G1-S phase, K-ras providing continuation of cell proliferation and cell immortality 13 and CDKN2A encoding two tumor suppressors (INK4a and ARF) and leading uncontrolled cell cycle progression by disrupting retinoblastoma (RB) and p53 pathways can be considered among these genes 19 .
CDC25A phosphatase is a new family of CDK phosphatases and their role is to activate CDK/cyclin complexes by dephosphorylating CDKs at different cell cycle checkpoints 20, 21 . CDC25A is expressed in late G1 phase and controls G1/S transition by activating CDK2/cyclin E complex 22 .
The CDC25B and C are very important for G2 phase and G2/M transition 23, 24 . Expression of CDC25A phosphatase in PDAC was evaluated in 48 patients in only one study in the literature and was found to be not increased in contrast to other malignancy studies 12 . In our study, we have evaluated more thoroughly CDC25A gene expression in the 28 patients and CDC25A gene polymorphisms in 118 patients and 83 healthy individuals. CDC25A expression and polymorphism assessment remained within normal limits in accordance with previous study. In contrast, the fact that CDC25A expression didn't show a significant difference between the normal and cancer tissues was not compatible with with the data found in previous studies on other tumor types.
Any effect of CDC25A which is a member of CDC25 gene family serving as a control step in cell division has not been found in pancreatic cancer. However, CDC25 gene family expression results in some studies performed on pancreatic cancer have shown that CDC25B has been responsible for pancreatic cancer 12 .
CONCLUSION
These results show that CDC25A from CDC25 gene family is not a gene taking active role in pancreatic cancer. However, the fact that CDC25A expression and polymorphism results are in normal range in pancreatic cancer doesn't mean that this gene has not any effect in pancreatic cancer. For better understanding of this case, examining the genetic pathway taking role in the regulation of CDC25A gene would provide real role of CDC25A gene in pancreatic cancer.
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